---
title: "News: Financial asset returns drive XTALPI to turn a profit of at least 100 million last year"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/278318791.md"
description: "The artificial intelligence drug development company XTALPI Co., Ltd. expects a net profit of no less than 100 million yuan last year, turning a profit mainly due to net gains from financial assets of no less than 500 million yuan and revenue growth to 780 million yuan. The company's core business losses have significantly narrowed, and there have been no further fair value losses on convertible redeemable preferred shares. The stock price on Wednesday was HKD 9.44, down 1.05%"
datetime: "2026-03-09T02:36:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278318791.md)
  - [en](https://longbridge.com/en/news/278318791.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278318791.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278318791.md) | [English](https://longbridge.com/en/news/278318791.md)


# News: Financial asset returns drive XTALPI to turn a profit of at least 100 million last year

Artificial intelligence drug development company **XTALPI** (2228.HK) announced on Tuesday that it expects to record a net profit of no less than 100 million yuan (14 million USD) for last year, compared to a loss of 1.517 billion yuan in the same period last year, achieving a turnaround to profitability.

The profit is attributed to several factors, primarily due to the recognition of financial assets measured at fair value through profit or loss, which recorded a net gain of no less than 500 million yuan, a significant increase compared to 25.3 million yuan in 2024. Additionally, the company's revenue also saw substantial growth, expected to be no less than 780 million yuan, an increase of at least 193% compared to approximately 266 million yuan in 2024, significantly narrowing the losses in its core business. The company also did not experience any fair value losses on convertible redeemable preferred shares in 2025.

XTALPI's main businesses include intelligent robotic solutions and drug discovery solutions. In June last year, the company completed a pipeline cooperation agreement with the U.S. innovative pharmaceutical company DoveTree, with a total order scale of approximately 5.99 billion USD.

The company's stock price opened higher but fell throughout the day, reporting 9.44 HKD at noon, down 1.05%. The stock has risen approximately 56% over the past 52 weeks.

_Li Shida_

### 相關股票

- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [XTALPI (02228.HK)](https://longbridge.com/zh-HK/quote/02228.HK.md)

## 相關資訊與研究

- [Qyuns Therapeutics' Arthritis Drug Crusekitug Accepted for Review in China; Shares Jump 11%](https://longbridge.com/zh-HK/news/278491064.md)
- [ZAWYA-PRESSR: Mubadala Bio expands access to critical cardiovascular medications](https://longbridge.com/zh-HK/news/278515357.md)
- [This 1 Little-Known AI Stock Is up 50% Already in 2026. Should You Buy It Now?](https://longbridge.com/zh-HK/news/278131143.md)
- [King's Flair Warns of 2025 Loss](https://longbridge.com/zh-HK/news/278688984.md)
- [08:25 ETPRAXTERA AI INSTITUTE WINS NATIONAL AWARD FOR AI TRAINING EXCELLENCE](https://longbridge.com/zh-HK/news/278107531.md)